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Abstract
Background: Patients undergoing major abdominal surgery are at high risk for developing venous thromboembolism
in the post-operative period. Current evidence-based guidelines recommend routine pharmacological venous
thromboembolism prophylaxis in patient at moderate to high risk post major abdominal surgery. However, the type of
agent, dose and duration of thromboprophylaxis remain unclear. We sought to survey current clinical practice and
assess for potential clinical equipoise regarding pharmacological thromboprophylaxis post major abdominal surgery.
Methods: An electronic survey targeting thrombosis expert members of Thrombosis Canada was conducted.
Results: The total response rate was 52.3% (45/86). All thrombosis experts recommended pharmacological
thromboprophylaxis for high risk patients post major abdominal surgery. Over 68% of the thrombosis experts
recommended thromboprophylaxis during hospitalization only. The majority of the participants recommended
using LMWH (85.9%) over UFH (10.1%). Approximately a third of the surveyed thrombosis experts estimated the
incidence of overall VTE at 7 to 10 days post-operatively in patients who do not receive thromboprophylaxis post
major abdominal surgery to be between 4 and 6%. A total of 55.3% of the thrombosis experts estimated the
incidence of PE to be between 0.5 and 1.0% for the same patient population. The risk of major bleeding episode was
estimated to be between 0.5 and 1% in patients receiving 7 to 10 days of pharmacological thromboprophylaxis in the
post-operative period by a majority of the thrombosis experts (68.4%). However, approximately 80% of thrombosis
experts believed that there is still some clinical equipoise around the use of thromboprophylaxis post discharge
(up to 7 to 10 days) in high risk adult patients post major abdominal surgery.
Conclusions: Thrombosis experts recommend LMWH prophylaxis post major abdominal surgery. There is still,
however, significant clinical equipoise regarding the duration of thromboprophylaxis (hospitalization only vs. total
to 7–10 days). The result of the survey might not be generalizable to non-academic centers and to other countries.
Background
Venous thromboembolism (VTE) is a condition associ-
ated with an increased morbidity and mortality among
hospitalized medical and post-surgical patients. The
most common presentations of venous thromboembol-
ism are deep vein thrombosis (DVT) of the lower ex-
tremity and pulmonary embolism (PE) [1]. Patients
undergoing major abdominal surgery (include any
abdominal surgery that is laparoscopic or open, per-
formed under general anaesthesia and lasted for at least
30 min) are at risk of developing a VTE complication in
the post-operative period. Their VTE risk depends on
both patient-specific and procedure specific factors [2].
Old age, previous VTE, cancer, obesity and prolonged
immobilization post-surgery are examples of high-risk
patient-specific factors. Examples of high-risk proce-
dures include open abdominal and pelvic surgeries,
abdominal-pelvic cancer surgery and bariatric surgery.
Based on those risk factors, the estimated baseline risk
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for VTE post major abdominal surgery in patients with
high risk factors for VTE is approximately 6% [2].
The American College of Chest Physician (ACCP)
Evidence-based consensus guidelines published in 2012
[2] recommend that patients undergoing non-orthopedic
surgery at moderate or high risk for VTE (general,
abdominal-pelvic or thoracic surgeries) receive routine
pharmacological thromboprophylaxis (Low molecular
weight heparin (LMWH), unfractionated heparin (UFH)
or fondaparinux). Although the efficacy and safety of
pharmacological thromboprophylaxis agents have been
proven, which agent to use (e.g. UFH vs. LMWH vs. fon-
daparinux) and at which dose (e.g. UFH 5,000 IU every
8 or 12 h) remains debatable. Furthermore, the duration
of pharmacological thromboprophylaxis (i.e. in-hospital
only vs. 7 to 10 days including an outpatient prescrip-
tion) is unclear. We sought to establish the current
clinical practice of Canadian thrombosis experts, assess
for potential clinical equipoise regarding pharmaco-
logical thromboprophylaxis in this patient population




The survey targeted thrombosis expert members of
Thrombosis Canada. Thrombosis Canada is an estab-
lished group of expert Canadian clinicians dedicated to
advancing education and research in the prevention and
treatment of thrombo-vascular disease [3]. Thrombosis
experts of Thrombosis Canada are defined as Canadian
clinicians who have made many significant contributions
to the body of knowledge in vascular medicine and dis-
seminated that knowledge through peer reviewed journal
publications and books as well authoring national and
international clinical practice guidelines. This expert
clinician group has the necessary expertise and experi-
ence to provide meaningful opinions on the planning of
a potential future randomized clinical trial (RCT).
Survey Monkey [4] online software was used to create
and distribute the survey. Each survey participant re-
ceived an email with hyperlink to the survey. A reminder
email with a link to the survey was sent weekly for 2
weeks. Our target response rate was 35% based on previ-
ously published response rate of physician specialist to
web-based survey [5]. The survey included a short intro-
duction to the survey, its goals/objectives and the reason
why the participant was chosen to participate. This was
followed by series of categorical questions (a total of 14)
with 4–5 answers, based on a short clinical vignette
(Please see Additional file 1: Appendix 1 on-line). The
first few questions were about the participant’s current
clinical practice. The following questions were related to
two different clinical scenarios. We surveyed participants
on their opinions on the efficacy and safety of pharma-
cological thromboprophylaxis and assessed if equipoise
still exist around its post major abdominal surgery. Fi-
nally, we asked the participants if they would consider
including their patients in a RCT, and if yes, to what
intervention, dose and duration. Participation in the sur-
vey was voluntary and all data were kept anonymous
and confidential. Filling out the online survey was
viewed as an implied consent. All response answers were
saved in the Survey Monkey online program, which was
later spread into Microsoft excel program in the form of
pooled data for analysis. Data was analyzed after
2 months of sending the survey.
Descriptive statistics (percentages) were used to
analyze and summarize the result of the survey. Simple
percentage compression were made between relevant
demographic subgroups. Analyses were conducted using
Survey Monkey online program.
Results
The initial response rate was 34.9% (30/86) and the total
response rate was 52.3% (45/86), of which only 37 com-
pleted the whole survey (43%).
The majority of the participants were hematologists
(40.5%) followed by internists (29.7%). Most participants
were males (67.6%) and middle age adults (age 46–55
(35.1%)) and the majority were in clinical practice for
more than 10 years (56.8%). Most responders were from
the province of Ontario (59.5%) and the majority (83.8%)
of the thrombosis experts practiced in an academic center.
All the thrombosis experts recommended the use of
thromboprophylaxis post major abdominal surgery. Ap-
proximately 70% percent (68.9%) recommended using
thromboprophylaxis during hospitalization only. The
others recommended extending thromboprophylaxis for
7–10 days or for a total of 28 days post major abdominal
surgery (26.7 and 4.4% respectively).
The majority of the thrombosis experts (85.9%) recom-
mended LMWH over UFH. Dalteparin 5,000 units daily
or enoxaparin 40 mg daily were the most frequently rec-
ommended regimens (33.3 and 24.2%, respectively).
Approximately a third of the thrombosis experts esti-
mated the incidence of overall VTE (symptomatic and
asymptomatic) at 7 to 10 days post-operatively in pa-
tients who do not receive thromboprophylaxis post
major abdominal surgery to be between 4 and 6%
whereas 55.3% estimated the incidence of PE to be be-
tween 0.5 and 1.0% in this patient population. The risk
of major bleeding episode was estimated to be between
0.5 and 1% in patients receiving 7 to 10 days of pharma-
cological thromboprophylaxis in the post-operative
period by a majority of the participants (68.4%). Finally,
a majority of thrombosis experts (57.9%) believe that the
benefits of using pharmacological thromboprophylaxis
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for 7 to 10 days in high-risk patients outweigh the risk
of bleeding in adult patients post major abdominal surgery
in most cases. However, approximately 80% thrombosis
experts believe that there is still some clinical equipoise
especially around the use of thromboprophylaxis post dis-
charge (up to 7 to 10 days) in high risk adult patients post
major abdominal surgery. Thus, it is not surprising that
they would consider allowing their patients to participate
in a RCT assessing the use of thromboprophylaxis in adult
patients post major abdominal surgery comparing differ-
ent duration (e.g. during hospitalization only vs. 10 days)
of thromboprophylaxis (89.5%).
Discussion
This survey of Canadian thrombosis experts shows that
there is an agreement in the use of pharmacological
thromboprophylaxis post major abdominal surgery. It
also shows that majority of the experts would use
thromboprophylaxis during hospitalization only. It also
confirms that there is clinical equipoise and uncertainty
around the use of thromboprophylaxis post discharge
(up to 7 to 10 days) in high-risk adult patients post
major abdominal surgery and that a clinical trial is
desirable.
A majority of the clinicians selected LMWH as their
preferred pharmacological thromboprophylactic agent.
This is not surprising given that LMWH have a better
safety profile compared to UFH. Unfractionated heparin
requires subcutaneous self-injections twice or three
times daily making them less convenient especially for
extended post discharge thromboprophylaxis. In
addition, UFH is associated with 2.6% risk of heparin in-
duced thrombocytopenia (HIT), a rare but potentially
serious adverse reaction causing low platelets with para-
doxical thrombosis and tissue necrosis [2]. LMWH is
less likely to cause HIT (0.2% compared to 2.6% with
UFH) [2]. Although it is also given subcutaneously, it is
usually given less frequently, usually once daily making
it more appealing than UFH for extended post discharge
thromboprophylaxis.
The majority of participants estimated the incidence of
PE between (0.5–1.0%) closely to the pooled estimates
previously reported (0.5%) [6]. However, they under esti-
mated the incidence of overall VTE at (4–6%) and major
bleed (0.5–1.0%) post major abdominal surgery (14.5
and 2.8%, respectively) [6].
It was not surprising that there is an agreement regard-
ing clinical equipoise around the use of thromboprophy-
laxis post discharge (up to 7 to 10 days) in high–risk adult
patients post major abdominal surgery. Although most of
clinical trials evaluated different pharmacological throm-
boprophylaxis for a fixed duration of 7 to 10 days, the sur-
gical techniques, post-operative management and length
of stay have changed significantly over recent years and
more contemporary data is desperately needed. Further-
more, there is a lack of clinical trials that directly
compared two different durations of thromboprophy-
laxis (in-hospital only vs. 7 to 10 days). Thus, the
majoring of the experts would consider participating
in a clinical trial comparing two different durations of
thromboprophylaxis.
It is important to acknowledge the limitations of our
cross sectional study. The survey was limited to Canadian
experts, mostly from academic centers, and therefore may
not reflect the opinion of other international experts or
clinicians and surgeons in community hospitals. Similarly,
the survey was not validated and tested in other popula-
tions. It would have been ideal to also capture the opin-
ions of the general surgeons. We piloted the survey in a
subgroup of members of the Canadian Association of
General Surgeons [7] . However, it was felt that the ques-
tions of VTE and major bleeding complication rates were
beyond the scope of their practice and be better defined
by a group of Thrombosis Medicine. Therefore, we sur-
veyed experts in the field to provide the most significant
and applicable opinion in the topic. Similarly, the mem-
bership of Thrombosis Canada is of relatively small size
and this might have resulted in potential selection
bias. Nonetheless, they remained the most important
clinical experts to survey. In addition, although the
overall response rate can be still considered low, it
exceeded our targeted response rate.
Conclusion
There is an agreement among thrombosis experts in
using LMWH for thromboprophylaxis post major ab-
dominal surgery. There is still equipoise around the use
of pharmacological thromboprophylaxis for 7–10 days
post-operatively including post discharge prescription.
There sms to be underestimation of major bleeding
events post major surgery in patients receiving pharma-
cological thromboprophylaxis. There is a need for a
RCT comparing the use of pharmacological thrombopro-
phylaxis in hospital only compared to duration of 7–10
days (including post discharge prescription) post major
abdominal surgery.
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